A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

87

Participants

Timeline

Start Date

May 14, 2021

Primary Completion Date

April 10, 2023

Study Completion Date

December 31, 2025

Conditions
Leukemia, LymphoidLymphoma, Non-HodgkinLymphoma, Mantle-CellLymphoma, Large B-Cell, DiffuseLymphoma, B-CellLymphoma, B-Cell, Marginal ZoneLeukemia, Lymphocytic, Chronic, B-Cell
Interventions
DRUG

LOXO-305

Administered orally.

Trial Locations (22)

71066

Affiliated Hospital of Hebei University, Baoding

100142

Beijing Cancer hospital, Beijing

130021

The First Hospital of Jilin University, Changchun

150081

Harbin Medical University Cancer Hospital, Harbin

200120

Shanghai East Hospital, Shanghai

210000

Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School, Nanjing

215066

The First Affiliated Hospital of Soochow University, Suzhou

241001

Wannan Medical College Yijishan Hospital, Wuhu

300020

Institute of hematology&blood disease hospital, Tianjin

300060

Tianjin Medical University Cancer Institute and Hospital, Tianjin

310022

Zhejiang Cancer Hospital, Hangzhou

410008

Xiangya Hospital Central South University, Changsha

410013

Hunan Cancer Hospital, Changsha

450008

Henan Cancer Hospital, Zhengzhou

471003

The First Affiliated Hospital of Henan University of Science &Technology, Luoyang Shi

510515

Southern Medical University Nanfang Hospital, Guangzhou

511400

Sun Yat-sen University Cancer Center, Guangzhou

570311

Hainan General Hospital, Haikou

610041

Sichuan Cancer Hospital, Chengdu

710126

Xi'an International Medical Center Hospital, Xi'an

830000

Xinjiang Medical University Cancer Hospital - Urumqi, Ürümqi

054031

Xingtai People's Hospital, Xingtai

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Loxo Oncology, Inc.

INDUSTRY

lead

Eli Lilly and Company

INDUSTRY

NCT04849416 - A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia) | Biotech Hunter | Biotech Hunter